165 related articles for article (PubMed ID: 9454815)
1. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models.
Jackson JR; Bolognese B; Hillegass L; Kassis S; Adams J; Griswold DE; Winkler JD
J Pharmacol Exp Ther; 1998 Feb; 284(2):687-92. PubMed ID: 9454815
[TBL] [Abstract][Full Text] [Related]
2. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
Underwood DC; Osborn RR; Kotzer CJ; Adams JL; Lee JC; Webb EF; Carpenter DC; Bochnowicz S; Thomas HC; Hay DW; Griswold DE
J Pharmacol Exp Ther; 2000 Apr; 293(1):281-8. PubMed ID: 10734180
[TBL] [Abstract][Full Text] [Related]
3. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
[TBL] [Abstract][Full Text] [Related]
5. Second-generation inhibitors demonstrate the involvement of p38 mitogen-activated protein kinase in post-transcriptional modulation of inflammatory mediator production in human and rodent airways.
Birrell MA; Wong S; McCluskie K; Catley MC; Hardaker EL; Haj-Yahia S; Belvisi MG
J Pharmacol Exp Ther; 2006 Mar; 316(3):1318-27. PubMed ID: 16368902
[TBL] [Abstract][Full Text] [Related]
6. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.
Hill RJ; Dabbagh K; Phippard D; Li C; Suttmann RT; Welch M; Papp E; Song KW; Chang KC; Leaffer D; Kim YN; Roberts RT; Zabka TS; Aud D; Dal Porto J; Manning AM; Peng SL; Goldstein DM; Wong BR
J Pharmacol Exp Ther; 2008 Dec; 327(3):610-9. PubMed ID: 18776065
[TBL] [Abstract][Full Text] [Related]
7. Suppression of lipopolysaccharide-induced cytokine production of gingival fibroblasts by a soybean, Kunitz trypsin inhibitor.
Kobayashi H; Yoshida R; Kanada Y; Fukuda Y; Yagyu T; Inagaki K; Kondo T; Kurita N; Suzuki M; Kanayama N; Terao T
J Periodontal Res; 2005 Dec; 40(6):461-8. PubMed ID: 16302924
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profile of AW-814141, a novel, potent, selective and orally active inhibitor of p38 MAP kinase.
Chopra P; Kulkarni O; Gupta S; Bajpai M; Kanoje V; Banerjee M; Bansal V; Visaga S; Chatterjee M; Chaira T; Shirumalla RK; Verma AK; Dastidar SG; Sharma G; Ray A
Int Immunopharmacol; 2010 Apr; 10(4):467-73. PubMed ID: 20093202
[TBL] [Abstract][Full Text] [Related]
9. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation.
Kwak HJ; Song JS; Heo JY; Yang SD; Nam JY; Cheon HG
J Pharmacol Exp Ther; 2005 Dec; 315(3):1188-95. PubMed ID: 16126838
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function.
Badger AM; Bradbeer JN; Votta B; Lee JC; Adams JL; Griswold DE
J Pharmacol Exp Ther; 1996 Dec; 279(3):1453-61. PubMed ID: 8968371
[TBL] [Abstract][Full Text] [Related]
11. Effect of the p38 MAPK inhibitor SB-239063 on Lipopolysaccharide-induced psychomotor retardation and peripheral biomarker alterations in rats.
Bison S; Razzoli M; Arban R; Michielin F; Bertani S; Carboni L
Eur J Pharmacol; 2011 Jul; 661(1-3):49-56. PubMed ID: 21545800
[TBL] [Abstract][Full Text] [Related]
12. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung.
Underwood DC; Osborn RR; Bochnowicz S; Webb EF; Rieman DJ; Lee JC; Romanic AM; Adams JL; Hay DW; Griswold DE
Am J Physiol Lung Cell Mol Physiol; 2000 Nov; 279(5):L895-902. PubMed ID: 11053025
[TBL] [Abstract][Full Text] [Related]
13. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis.
Badger AM; Griswold DE; Kapadia R; Blake S; Swift BA; Hoffman SJ; Stroup GB; Webb E; Rieman DJ; Gowen M; Boehm JC; Adams JL; Lee JC
Arthritis Rheum; 2000 Jan; 43(1):175-83. PubMed ID: 10643714
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of inhibitor selectivity in MAP kinases.
Wang Z; Canagarajah BJ; Boehm JC; Kassisà S; Cobb MH; Young PR; Abdel-Meguid S; Adams JL; Goldsmith EJ
Structure; 1998 Sep; 6(9):1117-28. PubMed ID: 9753691
[TBL] [Abstract][Full Text] [Related]
15. Potent inhibitors of the MAP kinase p38.
Henry JR; Rupert KC; Dodd JH; Turchi IJ; Wadsworth SA; Cavender DE; Schafer PH; Siekierka JJ
Bioorg Med Chem Lett; 1998 Dec; 8(23):3335-40. PubMed ID: 9873730
[TBL] [Abstract][Full Text] [Related]
16. 2-Acylaminopyridin-4-ylimidazoles as p38 MAP kinase inhibitors: Design, synthesis, and biological and metabolic evaluations.
Ziegler K; Hauser DR; Unger A; Albrecht W; Laufer SA
ChemMedChem; 2009 Nov; 4(11):1939-48. PubMed ID: 19731280
[TBL] [Abstract][Full Text] [Related]
17. Discovery of pyridazinopyridinones as potent and selective p38 mitogen-activated protein kinase inhibitors.
Wu B; Wang HL; Pettus L; Wurz RP; Doherty EM; Henkle B; McBride HJ; Saris CJ; Wong LM; Plant MH; Sherman L; Lee MR; Hsieh F; Tasker AS
J Med Chem; 2010 Sep; 53(17):6398-411. PubMed ID: 20712346
[TBL] [Abstract][Full Text] [Related]
18. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.
Wadsworth SA; Cavender DE; Beers SA; Lalan P; Schafer PH; Malloy EA; Wu W; Fahmy B; Olini GC; Davis JE; Pellegrino-Gensey JL; Wachter MP; Siekierka JJ
J Pharmacol Exp Ther; 1999 Nov; 291(2):680-7. PubMed ID: 10525088
[TBL] [Abstract][Full Text] [Related]
19. Role of p38 MAP kinase in LPS-induced airway inflammation in the rat.
Haddad EB; Birrell M; McCluskie K; Ling A; Webber SE; Foster ML; Belvisi MG
Br J Pharmacol; 2001 Apr; 132(8):1715-24. PubMed ID: 11309243
[TBL] [Abstract][Full Text] [Related]
20. SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia.
Barone FC; Irving EA; Ray AM; Lee JC; Kassis S; Kumar S; Badger AM; White RF; McVey MJ; Legos JJ; Erhardt JA; Nelson AH; Ohlstein EH; Hunter AJ; Ward K; Smith BR; Adams JL; Parsons AA
J Pharmacol Exp Ther; 2001 Feb; 296(2):312-21. PubMed ID: 11160612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
